USFDA pulls up Cipla for manufacturing lapses at Pithampur plant

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. "Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed," the USFDA stated in the letter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOvVBD4
via IFTTT